| Genetic screens identify host factors for SARS-CoV-2 and common cold coronaviruses R Wang, CR Simoneau, J Kulsuptrakul, M Bouhaddou, KA Travisano, ... Cell 184 (1), 106-119. e14, 2021 | 337 | 2021 |
| The antiviral and cancer genomic DNA deaminase APOBEC3H is regulated by an RNA-mediated dimerization mechanism NM Shaban, K Shi, KV Lauer, MA Carpenter, CM Richards, D Salamango, ... Molecular cell 69 (1), 75-86. e9, 2018 | 71 | 2018 |
| The binding interface between human APOBEC3F and HIV-1 Vif elucidated by genetic and computational approaches C Richards, JS Albin, Ö Demir, NM Shaban, EM Luengas, AM Land, ... Cell reports 13 (9), 1781-1788, 2015 | 45 | 2015 |
| The human disease gene LYSET is essential for lysosomal enzyme transport and viral infection CM Richards, S Jabs, W Qiao, LD Varanese, M Schweizer, PR Mosen, ... Science 378 (6615), eabn5648, 2022 | 38 | 2022 |
| Genetic and mechanistic basis for APOBEC3H alternative splicing, retrovirus restriction, and counteraction by HIV-1 protease D Ebrahimi, CM Richards, MA Carpenter, J Wang, T Ikeda, JT Becker, ... Nature communications 9 (1), 4137, 2018 | 31 | 2018 |
| A memory of eS25 loss drives resistance phenotypes AG Johnson, RA Flynn, CP Lapointe, YS Ooi, ML Zhao, CM Richards, ... Nucleic Acids Research 48 (13), 7279-7297, 2020 | 12 | 2020 |
| Autoantibodies are highly prevalent in non–SARS-CoV-2 respiratory infections and critical illness A Feng, EY Yang, AR Moore, S Dhingra, SE Chang, X Yin, R Pi, ... JCI insight 8 (3), 2023 | 11 | 2023 |
| Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections. A Feng, E Yang, A Moore, S Dhingra, S Chang, X Yin, R Pi, E Mack, ... Research Square, 2022 | 8 | 2022 |
| Reassessing APOBEC3G inhibition by HIV-1 Vif-derived peptides CM Richards, M Li, AL Perkins, A Rathore, DA Harki, RS Harris Journal of molecular biology 429 (1), 88-96, 2017 | 8 | 2017 |
| Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV R Mateo, S Xu, A Shornikov, T Yazdi, Y Liu, L May, B Han, D Han, ... JHEP Reports 5 (11), 100893, 2023 | 5 | 2023 |
| No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta J Hollnberger, Y Liu, S Xu, S Chang, R Martin, S Manhas, T Aeschbacher, ... Journal of Hepatology 79 (3), 657-665, 2023 | 5 | 2023 |
| APOBEC3B lysine residues are dispensable for DNA cytosine deamination, HIV-1 restriction, and nuclear localization AM Molan, HM Hanson, CM Chweya, BD Anderson, GJ Starrett, ... Virology 511, 74-81, 2017 | 5 | 2017 |
| Another Method for Determining the Pressure inside an Intact Carbonated Beverage Can (or Bottle) TS Kuntzleman, C Richards Journal of chemical education 87 (9), 993-993, 2010 | 4 | 2010 |
| MYADM binds human parechovirus 1 and is essential for viral entry W Qiao, CM Richards, Y Kim, JR Zengel, S Ding, HB Greenberg, ... Nature Communications 15 (1), 3469, 2024 | | 2024 |
| 1306. Lower Treatment Failure Rates in Patients with Non-Staphylococcal Prosthetic Joint Infections (PJI) Treated with Debridement and Implant Retention (DAIR) Receiving … P Sekar, J Merchant, B Alexander, K Miell, B Beck, R Nair, D Suh, ... Open forum infectious diseases 10 (Supplement_2), ofad500. 1145, 2023 | | 2023 |
| NO DETECTABLE RESISTANCE TO BULEVIRTIDE MONOTHERAPY THROUGH 96 WEEKS TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS D S Aleman, Y Liu, S Xu, S Chang, R Martin, T Aeschbacher, L May, ... HEPATOLOGY 78, S398-S399, 2023 | | 2023 |
| NO RESISTANCE TO TENOFOVIR ALAFENAMIDE (TAF) IN ADULT, HBEAG-POSITIVE AND HBEAG-NEGATIVE PARTICIPANTS WITH CHRONIC HEPATITIS B INFECTION TREATED WITH TAF FOR UP TO 8 YEARS. R Mateo, HLY Chan, P Marcellin, CP Pan, T Yazdi, S Chang, D Han, ... HEPATOLOGY 78, S532-S533, 2023 | | 2023 |
| LYSET/TMEM251-a novel key component of the mannose 6-phosphate pathway W Qiao, CM Richards, S Jabs Autophagy 19 (7), 2143-2145, 2023 | | 2023 |
| Preliminary results of a Phase 1b, open-label, multicenter study of selgantolimod (GS-9688) in special populations of patients with chronic hepatitis B K Agarwal, PN Cheng, CJ Liu, R Duan, N Kolhatkar, R Mateo, B Da, ... Journal of Hepatology 78, S1159-S1160, 2023 | | 2023 |
| HIV-1 Counteraction Mechanisms versus APOBEC3-Mediated Restriction CM Richards University of Minnesota, 2018 | | 2018 |
